Related Experiment Video
Updated: Jul 8, 2026

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach?
Konstantinos Spengos1, Christos Theleritis, Thomas Paparrigopoulos
1Department of Neurology, University of Athens School of Medicine, Eginition Hospital, Athens, Greece.
Abstract:
We present the case of a woman with chronic migraine who unexpectedly reported full remission of headache after memantine, an NMDA receptor antagonist, was administered for treating concomitant mild cognitive impairment. An underlying dose-dependent effect of memantine on headache symptoms in chronic daily headache and chronic migraine could be assumed.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

